PATIENT SURVIVAL WITH ypT0N+ FOLLOWING NEOADJUVANT THERAPY IN GASTRIC AND RECTAL CANCERS
Author
Elshami, Mohamedraed
Metadata
Show full item recordCitation
Elshami, Mohamedraed. 2021. PATIENT SURVIVAL WITH ypT0N+ FOLLOWING NEOADJUVANT THERAPY IN GASTRIC AND RECTAL CANCERS. Master's thesis, Harvard Medical School.Abstract
BackgroundSurvival outcomes of gastric and rectal cancer patients who developed ypT0N+ remain poorly characterized.
Methods
A survival analysis of the NCDB was conducted on patients with gastric or rectal adenocarcinoma who underwent neoadjuvant therapy and surgery.
Results
Among gastric cancer patients, achieving ypT0N+ was associated with lower 5-year and 3-year overall survival (OS) than ypT0N0 and ypT1-2N0. There were no differences in 1-year OS between ypT0N+ and ypT0N0 or ypT1-2N0. There were also no differences in 5-year, 3-year, or 1-year OS between ypT0N+ and ypT3-4N0 or ypT1-2N+. Developing ypT0N+ was associated with a higher 5-year OS than ypT3-4N+. There were no differences in 3-year or 1-year OS between ypT0N+ and ypT3-4N+.
.
Among rectal cancer patients who received total neoadjuvant therapy, developing ypT0N+ was associated with a lower 5-year OS than ypT0N0 and ypT1-2N0. However, ypT0N+ disease was associated with a higher 5-year OS than ypT3-4N+. There were no differences in 5-year OS between ypT0N+ and ypT3-4N0 or ypT1-2N+. Similar findings were noticed among rectal cancer patients who received neoadjuvant chemoradiation and adjuvant chemotherapy.
Conclusion
Developing ypT0N+ was associated with a lower 5-year OS than ypT0N0 and ypT1-2N0 and a higher 5-year OS than ypT3-4N+ in both gastric and rectal cancers.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37368009
Collections
Contact administrator regarding this item (to report mistakes or request changes)